Effectiveness and safety of secukinumab in axial spondyloarthritis: a 24-month prospective, multicenter real-life study

Effectiveness and safety of secukinumab in axial spondyloarthritis: a 24-month prospective, multicenter real-life study

Objectives: To evaluate, in a multicentric Italian cohort of axial spondyloarthritis (axSpA) patients on Secukinumab (SEC) followed for 24 months: (1) the long-term effectiveness and safety of SEC; (2) the drug retention rate and low disease activity (LDA) measured as Bath Ankylosing Spondylitis Dis...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Therapeutic advances in musculoskeletal disease 2022, Vol.14, p.1759720X221090310-1759720X221090310
Hauptverfasser: Ramonda, Roberta, Lorenzin, Mariagrazia, Sole Chimenti, Maria, D’Angelo, Salvatore, Marchesoni, Antonio, Salvarani, Carlo, Lubrano, Ennio, Costa, Luisa, Dal Bosco, Ylenia, Fracassi, Elena, Ortolan, Augusta, Ferraioli, Mario, Carriero, Antonio, Visalli, Elisa, Bixio, Riccardo, Desiati, Francesca, Bergamini, Alberto, Pedrollo, Elisa, Doria, Andrea, Foti, Rosario, Carletto, Antonio
Format: Artikel
Sprache:eng
Schlagworte:
Arthritis
Clinical outcomes
Monoclonal antibodies
Musculoskeletal diseases
Original Research
Patient safety
Side effects
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Objectives: To evaluate, in a multicentric Italian cohort of axial spondyloarthritis (axSpA) patients on Secukinumab (SEC) followed for 24 months: (1) the long-term effectiveness and safety of SEC; (2) the drug retention rate and low disease activity (LDA) measured as Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 
ISSN:1759-720X
1759-7218
DOI:10.1177/1759720X221090310